26th Apr 2021 11:54
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 23 April 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD |
|
| ||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
1,726,450 | 1.34% | 167,458 | 0.13% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 7,134 | 0.01% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,804,909 | 1.40% | 180,692 | 0.14% | ||
|
|
|
| ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
| Purchase | 2 | 233.8900 USD |
| Purchase | 7 | 233.3964 USD |
| Purchase | 8 | 233.8500 USD |
| Purchase | 10 | 233.9200 USD |
| Purchase | 16 | 233.6900 USD |
| Purchase | 33 | 233.9593 USD |
| Purchase | 43 | 232.9900 USD |
| Purchase | 54 | 233.9642 USD |
| Purchase | 100 | 232.9000 USD |
| Purchase | 100 | 234.2100 USD |
| Purchase | 100 | 233.9100 USD |
| Purchase | 100 | 233.6750 USD |
| Purchase | 144 | 232.7852 USD |
| Purchase | 200 | 234.0100 USD |
| Purchase | 246 | 233.9005 USD |
| Purchase | 400 | 233.8800 USD |
| Purchase | 400 | 233.9175 USD |
| Purchase | 525 | 233.7220 USD |
| Purchase | 541 | 233.4221 USD |
| Purchase | 700 | 233.8894 USD |
| Purchase | 710 | 233.6598 USD |
| Purchase | 866 | 233.7797 USD |
| Purchase | 923 | 233.8417 USD |
| Purchase | 998 | 233.6979 USD |
| Purchase | 1,100 | 233.7748 USD |
| Purchase | 2,322 | 233.8009 USD |
| Purchase | 3,002 | 233.7849 USD |
| Purchase | 3,915 | 233.2729 USD |
| Purchase | 5,140 | 232.8900 USD |
| Purchase | 6,226 | 233.6593 USD |
| Purchase | 6,719 | 233.4798 USD |
| Purchase | 9,006 | 232.8945 USD |
| Purchase | 27,581 | 233.4351 USD |
| Sale | 5 | 233.2680 USD |
| Sale | 10 | 233.9200 USD |
| Sale | 32 | 234.0000 USD |
| Sale | 43 | 232.9900 USD |
| Sale | 44 | 232.7972 USD |
| Sale | 100 | 232.7800 USD |
| Sale | 100 | 233.9700 USD |
| Sale | 100 | 233.8600 USD |
| Sale | 108 | 233.8500 USD |
| Sale | 109 | 233.7183 USD |
| Sale | 133 | 233.2305 USD |
| Sale | 200 | 234.0100 USD |
| Sale | 200 | 233.9975 USD |
| Sale | 268 | 233.3052 USD |
| Sale | 300 | 233.9033 USD |
| Sale | 601 | 233.1246 USD |
| Sale | 817 | 233.2878 USD |
| Sale | 1,100 | 233.7748 USD |
| Sale | 1,339 | 233.8048 USD |
| Sale | 1,400 | 233.8894 USD |
| Sale | 1,886 | 232.8900 USD |
| Sale | 2,939 | 233.0195 USD |
| Sale | 3,788 | 232.8905 USD |
| Sale | 5,902 | 233.5064 USD |
| Sale | 6,118 | 233.5147 USD |
| Sale | 7,592 | 233.6900 USD |
| Sale | 8,906 | 232.8934 USD |
| Sale | 29,729 | 233.5230 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 26 Apr 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | |
|
| to which the option |
| ||
|
| or derivative |
| ||
|
| relates |
| ||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005405/en/
Copyright Business Wire 2021
Related Shares:
Barclays